{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:05:38Z","timestamp":1791299138108,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Institut National de Veille Sanitaire (InVS)"},{"name":"Direction G\u00e9n\u00e9rale de l'Armement","award":["07CO301"],"award-info":[{"award-number":["07CO301"]}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ijantimicag.2017.03.022","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T14:47:43Z","timestamp":1499352463000},"page":"377-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis , including in tularaemia patients with treatment failure"],"prefix":"10.1016","volume":"50","author":[{"given":"V.","family":"Sutera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-0697","authenticated-orcid":false,"given":"G.","family":"Hoarau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Renesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Caspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-3208","authenticated-orcid":false,"given":"M.","family":"Maurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0010","series-title":"WHO guidelines on tularaemia","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0015","series-title":"Biosafety in Microbiological and Biomedical Laboratories (BMBL)","author":"CDC","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1409.009","article-title":"Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations","volume":"1105","author":"Sj\u00f6stedt","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14787210.6.2.231","article-title":"Tularemia: current diagnosis and treatment options","volume":"6","author":"Hepburn","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0030","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1196\/annals.1409.017","article-title":"New approaches to diagnosis and therapy of tularemia","volume":"1105","author":"T\u00e4rnvik","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00005792-198507000-00006","article-title":"Tularemia: a 30-year experience with 88 cases","volume":"64","author":"Evans","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0040","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1093\/cid\/cir612","article-title":"Human tularemia in France, 2006\u20132010","volume":"53","author":"Maurin","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0045","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa011374","article-title":"An outbreak of primary pneumonic tularemia on Martha's Vineyard","volume":"345","author":"Feldman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/00365540110080773","article-title":"In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis","volume":"34","author":"Johansson","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0055","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.01584-07","article-title":"In vitro susceptibility of isolates of Francisella tularensis types A and B from North America","volume":"52","author":"Urich","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0060","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/jac\/dkr338","article-title":"Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey","volume":"66","author":"Yesilyurt","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0065","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.29.20858","article-title":"Characterisation of a new group of Francisella tularensis subsp. holarctica in Switzerland with altered antimicrobial susceptibilities, 1996 to 2013","volume":"19","author":"Origgi","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0070","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1128\/AAC.44.12.3428-3431.2000","article-title":"Bactericidal activities of antibiotics against intracellular Francisella tularensis","volume":"44","author":"Maurin","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fcimb.2014.00036","article-title":"A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis","volume":"4","author":"Sutera","year":"2014","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0080","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1128\/AAC.00390-10","article-title":"Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus)","volume":"54","author":"Nelson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jac\/dki359","article-title":"In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice","volume":"56","author":"Piercy","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0090","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1128\/AAC.01104-12","article-title":"Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection","volume":"56","author":"Rotem","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0095","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/cid\/cis706","article-title":"Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases","volume":"55","author":"Weber","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1086\/321825","article-title":"Ciprofloxacin for treatment of tularemia","volume":"33","author":"Johansson","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0105","first-page":"744","article-title":"Tularemia\u2014Missouri, 2000\u20132007","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1086\/322601","article-title":"Tularemia epidemic in northwestern Spain: clinical description and therapeutic response","volume":"33","author":"P\u00e9rez-Castrill\u00f3n","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0463.2008.00901.x","article-title":"Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia","volume":"116","author":"Meric","year":"2008","journal-title":"APMIS"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/dkt321","article-title":"Evolution toward high-level fluoroquinolone resistance in Francisella species","volume":"69","author":"Sutera","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.mcp.2010.01.003","article-title":"Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis","volume":"24","author":"Loveless","year":"2010","journal-title":"Mol Cell Probes"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0135","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1101\/gr.071266.107","article-title":"Rapid comparative genomic analysis for clinical microbiology: the Francisella tularensis paradigm","volume":"18","author":"La Scola","year":"2008","journal-title":"Genome Res"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0140","doi-asserted-by":"crossref","first-page":"534","DOI":"10.7883\/yoken.66.534","article-title":"In vitro antibiotic susceptibility of Francisella tularensis isolates from Japan","volume":"66","author":"Hotta","year":"2013","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0145","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/jac\/dks238","article-title":"Standardized broth microdilution antimicrobial susceptibility testing of Francisella tularensis subsp. holarctica strains from Europe and rare Francisella species","volume":"67","author":"Georgi","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0150","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jac\/dks399","article-title":"Antimicrobial susceptibility of Francisella tularensis subsp. holarctica strains from Hungary, Central Europe","volume":"68","author":"Kreizinger","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0155","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijantimicag.2005.07.003","article-title":"Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains","volume":"26","author":"Tomaso","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0165","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkq315","article-title":"Phenotypic and genetic characterization of macrolide resistance in Francisella tularensis subsp. holarctica biovar I","volume":"65","author":"Gestin","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0170","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0175","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3201\/eid1905.120377","article-title":"Treatment of tularemia in patient with chronic graft-versus-host disease","volume":"19","author":"Weile","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0180","doi-asserted-by":"crossref","first-page":"20956","DOI":"10.2807\/1560-7917.ES2014.19.45.20956","article-title":"10 years of surveillance of human tularaemia in France","volume":"19","author":"Mailles","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0185","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/jac\/dkg222","article-title":"Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection","volume":"51","author":"Ruiz","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0190","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/fmb.10.96","article-title":"Antibiotic resistance in Chlamydiae","volume":"5","author":"Sandoz","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0195","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ebiom.2015.07.018","article-title":"Hidden selection of bacterial resistance to fluoroquinolones in vivo: the case of Legionella pneumophila and humans","volume":"2","author":"Shadoud","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.12688\/f1000research.6709.2","article-title":"Individuality, phenotypic differentiation, dormancy and \u2018persistence\u2019 in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology","volume":"4","author":"Kell","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.ijantimicag.2017.03.022_bib0205","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1574-6968.2007.01033.x","article-title":"The AcrAB RND efflux system from the live vaccine strain of Francisella tularensis is a multiple drug efflux system that is required for virulence in mice","volume":"279","author":"Bina","year":"2008","journal-title":"FEMS Microbiol Lett"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T16:42:04Z","timestamp":1569688924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924857917302510"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.022","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis, including in tularaemia patients with treatment failure","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}